Thank you Irene Fernandez-Ruiz for this great piece of commentary in @natrevcardiol.nature.com on the IVORY trial published in @natmed.nature.com Main paper can be found here: rdcu.be/eX8W3 @ziadmallat.bsky.social @18fdg.bsky.social @vpd-hlri.bsky.social @medcambridge.bsky.social

Nature Reviews Cardiology@natrevcardiol.nature.com · 7mo ago

New online! Low-dose IL-2 therapy reduces arterial inflammation in acute coronary syndromes #CardioSky

Fresh off her @naturemedicine.bsky.social paper. @rouchelles.bsky.social talks balancing work and life, navigating academic cardiology as a woman, and why even top achievers face imposter syndrome. Read more ⬇️ rdcu.be/eX8W3 @nihr.bsky.social @royalpapworth.bsky.social

Please do have a listen to @rouchelles.bsky.social sharing her thoughts about her science, balancing a clinical academic career in cardiology with family life, & the importance of mentors and a supportive environment. @nihr.bsky.social @royalpapworth.bsky.social @cam.ac.uk

VPD Heart & Lung Research Institute@vpd-hlri.bsky.social · 7mo ago

Fresh off her @naturemedicine.bsky.social paper. @rouchelles.bsky.social talks balancing work and life, navigating academic cardiology as a woman, and why even top achievers face imposter syndrome. Read more ⬇️ rdcu.be/eX8W3 @nihr.bsky.social @royalpapworth.bsky.social

Thank you Elisa Martini for featuring the IVORY trial published in @natmed.nature.com in Nature Portfolio’s Nature CVR 🫀 Main paper: rdcu.be/eX8W3 Commentary: rdcu.be/eYyG6 @jch403.bsky.social @ziadmallat.bsky.social @18fdg.bsky.social @ivorytrial.bsky.social @mallatlab.bsky.social

In a phase 2 trial, low-dose interleukin-2 boosted regulatory T cells and reduced arterial inflammation in acute coronary syndrome patients compared to placebo. https://www.nature.com/articles/s41591-025-04090-y

Amazing to be part of this team - please read the paper and let us know what you think! @rouchelles.bsky.social

@rouchelles.bsky.social · 7mo ago

The IVORY trial was published in Nature Medicine last week. rdcu.be/eX8W3 This trial done in high-risk individuals who presented with heart attacks 🫀, showed low-dose interleukin-2 led to a ⬆️ Regulatory T cells ⬇️ Arterial inflammation 🔥 ⬇️ trend in adverse cardiovascular outcomes ❤️‍🔥 at 2 years

A potential breakthrough in heart disease Cambridge medics tested a low-dose drug that ⬇️inflammation in blood vessels by ⬆️ protective immune cells. This mechanism won the 2025 Nobel Prize for Medicine Over 2 years Drug group: 0 events, placebo 11% www.nature.com/articles/s41... #HeartHealth

The IVORY trial was published in Nature Medicine last week. rdcu.be/eX8W3 This trial done in high-risk individuals who presented with heart attacks 🫀, showed low-dose interleukin-2 led to a ⬆️ Regulatory T cells ⬇️ Arterial inflammation 🔥 ⬇️ trend in adverse cardiovascular outcomes ❤️‍🔥 at 2 years

Thank you @vpd-hlri.bsky.social for the shout-out. Original article here: rdcu.be/eX8W3

VPD Heart & Lung Research Institute@vpd-hlri.bsky.social · 7mo ago

IVORY trial results published! 🫀 Early results show reduced artery inflammation and a trend towards fewer future heart events. www.cam.ac.uk/research/news/targeting-the-immune-system-could-prevent-future-heart-attacks-clinical-trial-suggests

Original article: rdcu.be/eX8W3

Inserm@inserm.fr · 7mo ago

Dans un essai clinique de phase 2, une équipe de l'Inserm montre l’efficacité d’un nouveau traitement pour réduire l'inflammation chronique ou résiduelle qui peut être observée après un syndrome coronaire aigu (SCA). Lire le communiqué : presse.inserm.fr/syndrome-cor...

Pr Z Mallat @PARCC and colleagues show that, in patients with acute coronary syndromes, low-dose IL-2 safely increases Treg cell levels and reduces arterial inflammation. Learn More: www.nature.com/articles/s41...

Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial - Nature Medicine

In a randomized phase 2 trial in patients with acute coronary syndrome and high levels of the inflammation biomarker C-reactive protein, treatment with low-dose interleukin-2 increased the numbers of ...

nature.com

After 6 weeks of Rx patients with ACSs, low-dose IL-2 safely increases Tregcell levels and reduces arterial inflammation. www.nature.com/articles/s41...

Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial - Nature Medicine

In a randomized phase 2 trial in patients with acute coronary syndrome and high levels of the inflammation biomarker C-reactive protein, treatment with low-dose interleukin-2 increased the numbers of ...

nature.com

Delighted to share that the results of the IVORY trial were published in Nature Medicine: rdcu.be/eX8W3 This marks a significant scientific milestone for the field and the translational journey of low-dose IL-2.